Arie Belldegrun

Arie S. Belldegrun
Born	Birth date -1st March 1966 Israel
Nationality	Israeli-American
Occupation	Urologic oncologist Businessman Investor
Known for	Contributions to urologic oncology, entrepreneurship in biotechnology

Arie S. Belldegrun, FACS, (born 1949) is an Israeli-American urologic oncologist, billionaire businessman, and investor known for his significant contributions to cancer treatment and the biotechnology industry. As a pioneer in the field of urologic oncology, Belldegrun has played a pivotal role in the development of innovative cancer therapies, particularly in the area of kidney cancer and bladder cancer. His entrepreneurial spirit has led to the founding of several successful biotechnology companies, including Kite Pharma, which has been at the forefront of developing CAR T-cell therapy for cancer.

Early Life and Education

Born in Israel in 1949, Arie Belldegrun completed his medical degree at the Hebrew University of Jerusalem. He then moved to the United States for further training, where he completed a residency in urologic surgery and a fellowship in urologic oncology at the Harvard Medical School and its affiliated hospitals. Belldegrun's early interest in cancer research and treatment led him to pursue additional studies in immunology and biotechnology.

Career

Medical Career

As a urologic oncologist, Belldegrun has worked extensively on the surgical treatment of urological cancers, with a focus on innovative approaches to kidney cancer and bladder cancer. His research has contributed to advancements in minimally invasive surgical techniques and the development of novel immunotherapies.

Entrepreneurship and Business Ventures

Belldegrun's entrepreneurial career began with the founding of Agensys, a company focused on developing antibody-based cancer therapies. However, he is perhaps best known for founding Kite Pharma, a biotechnology company specializing in the development of CAR T-cell therapies for cancer. Under Belldegrun's leadership, Kite Pharma developed and commercialized one of the first CAR T-cell therapies, leading to its acquisition by Gilead Sciences for nearly $12 billion.

Belldegrun has also founded or co-founded several other biotechnology companies and investment firms focused on advancing innovative healthcare solutions, including Allogene Therapeutics and Vida Ventures.

Contributions to Medicine and Science

Belldegrun's work in urologic oncology and cancer immunotherapy has had a profound impact on the treatment of cancer. His efforts in developing CAR T-cell therapy represent a significant breakthrough in personalized medicine, offering new hope to patients with previously untreatable forms of cancer.

Philanthropy

Beyond his professional achievements, Belldegrun has engaged in various philanthropic activities, focusing on education, healthcare, and the support of scientific research.

Awards and Recognition

Over his career, Belldegrun has received numerous awards and honors in recognition of his contributions to medicine, science, and business.

See Also

• Urologic oncology
• Immunotherapy
• CAR T-cell therapy
• Biotechnology